Share this article on:

From hypertension to hypertrophy to heart failure: the role of cardiotrophin-1

Schillaci, Giuseppea,b; Pucci, Giacomoa,b; Perlini, Stefanoc

doi: 10.1097/HJH.0b013e32835ed4bb
Editorial Commentaries

aDipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Perugia

bStruttura Complessa di Medicina Interna, Ospedale ‘S. Maria’, Terni

cClinica Medica II, Dipartimento di Medicina Interna, Fondazione IRCCS San Matteo, Università di Pavia, Italy

Correspondence to Professor Giuseppe Schillaci, Unità di Medicina Interna, Università degli Studi di Perugia, Ospedale ‘S. Maria’, viale Tristano di Joannuccio, 1, IT-05100 Terni, Italy. Tel: +39 0744 205201; e-mail:

Heart failure is a major and growing public health issue, with high prevalence, poor clinical outcomes, and large healthcare costs [1]. Hypertension, a leading risk factor for congestive heart failure, represents the most common comorbidity in patients with heart failure [2], and carries an attributable risk of over 40% at the population level [3]. According to the American College of Cardiology/American Heart Association guidelines, all hypertensive patients without symptoms of heart failure and without structural heart disease should be classified as belonging to stage A, which denotes a high risk for heart failure, whereas those with structural heart involvement denoted, for instance, by left ventricular (LV) hypertrophy should be classified as belonging to stage B [4].

Transition from hypertension to overt heart failure is characterized by a number of functional and structural alterations, which include LV hypertrophy and asymptomatic LV systolic and diastolic dysfunction [5]. Although LV systolic chamber function is almost invariably normal or even above normal in uncomplicated patients with essential hypertension [6,7], the use of the more physiologic midwall mechanic indexes identifies reduced myocardial systolic function in a large subgroup of hypertensive patients, whose chamber function is still preserved thanks to a more concentric LV geometry [8–9]. In individuals with untreated essential hypertension, the prevalence of asymptomatic LV systolic dysfunction is as low as 4% when considering traditional endocardial or chamber mechanics [10,11], and increases to 18% when assessed through midwall fractional shortening [10]. Also, midwall fractional shortening has a strong, independent, inverse relationship with a number of prognostically adverse markers including relative wall thickness as an index of LV concentric geometry [12], LV mass [12], and an inappropriately high LV mass, that is, beyond values required to compensate cardiac workload at a given body size and sex [13]. The coexistence of a low midwall fractional shortening and a high LV mass identifies a subgroup of hypertensive patients at a particularly high risk for cardiac morbidity and mortality [14]. Moreover, LV hypertrophy regression and normalization of chamber geometry during antihypertensive treatment are associated with improved midwall function [15].

Epidemiological studies have identified clinical and demographic factors that increase the risk of developing LV systolic dysfunction in hypertension, including age, male sex, smoking, LV hypertrophy, and uncontrolled blood pressure [10,12,16]. However, knowledge of these risk factors alone cannot provide the means to predict the presence of systolic dysfunction, holds no real specificity and sensitivity, and is not useful in a clinically relevant context. As such, analytic measurements that would be easy to use and cost-effective for the detection of LV systolic dysfunction in an ambulatory setting would have significant clinical import. Although hemodynamic factors play a well recognized role in the transition from hypertension to heart failure, the role of a wide array of nonhemodynamic factors has also been recognized [17,18]. Table 1 provides a list of biological markers that have been associated to LV systolic dysfunction.

In 2005, González et al.[19] proposed cardiotrophin-1, a cytokine belonging to the interleukin 6 family, as a new serological marker for LV mass, suggesting its use in serial assessment of hypertensive cardiac damage. Indeed, cardiotrophin-1 induces cell proliferation, hypertrophy, and secretion of extracellular matrix proteins in aortic vascular smooth muscle cells both in vitro[20] and in vivo[21], suggesting a role for cardiotrophin-1 in arterial fibrosis and stiffness. Moreover, elevated plasma concentrations of cardiotrophin-1 have been reported in patients with a variety of diseases, including hypertension [22] and aortic stenosis [23], indicating that this cytokine may contribute to the development of chronic pressure overload LV hypertrophy and dysfunction. Two recent studies also suggest a potentially important role of cardiotrophin-1 in the development of cardiovascular fibrosis. On the contrary, in normotensive Wistar rats chronic cardiotrophin-1 administration induces blood pressure-independent cardiac, vascular and renal fibrosis, associated with increased LV volumes, reduced fractional shortening and ejection fraction, vascular media thickening, and increased arterial stiffness and glomerular and tubulointerstitial fibrosis. [21]. On the contrary, lifelong cardiotrophin-1 absence increases median longevity in senescent cardiotrophin-1-null mice together with decreased arterial fibrosis, stiffness, and senescence, likely through downregulating apoptotic, senescence, and inflammatory pathways [24].

The role of cardiotrophin-1 in hypertensive heart disease is also supported by a number of clinical studies. López et al.[22] found that plasma cardiotrophin-1 was higher in hypertensive patients than in normotensive controls, and even higher in the presence of hypertensive LV hypertrophy. Other studies from the same research group reported a cross-sectional association in hypertensive patients of plasma cardiotrophin-1 with inappropriately high LV mass [25] and with clinically overt heart failure [26]. Interestingly, treatment-induced decrease of plasma cardiotrophin-1 paralleled LV hypertrophy regression in treated hypertension [19,25]. Data also support an association between cardiotrophin-1 and LV mass in other pathologic states, including hypertrophic [27] and dilated cardiomyopathy [28]. Other authors could not confirm, however, the above findings. In a study carried out in 446 patients, plasma cardiotrophin-1 levels did not allow to discriminate referent healthy control patients from patients with LV hypertrophy but no evidence of heart failure, and patients with LV hypertrophy and diastolic heart failure [29]. In the same study, a panel of biomarkers of extracellular matrix remodeling and myocyte stress, including matrix metalloproteinases, tissue inhibitors of metalloproteinases, procollagen peptides, and N-terminal probrain natriuretic peptide, were able to predict the presence of LV hypertrophy and diastolic heart failure [29].

In the current issue of the Journal, Ravassa et al.[30] report on the relationship between cardiotrophin-1 and LV systolic function in human hypertension. Serum cardiotrophin-1 was significantly higher in 278 patients with essential hypertension and LV ejection fraction more than 50% than in 25 healthy controls. More importantly, in hypertensive patients serum cardiotrophin-1 concentration had an inverse correlation with LV midwall fractional shortening, which was independent of the presence of LV hypertrophy, or inappropriately high LV mass.

The impact of serum cardiotrophin-1 on asymptomatic LV systolic dysfunction had not been compared directly previously in hypertensive patients. In this regard, the study by Ravassa et al.[30] is original and conveys new, clinically relevant information, which suggests that determination of serum cardiotrophin-1 might serve as a test for screening hypertensive heart disease. Nonetheless, the study leaves some questions open. First, although the relation between cardiotrophin-1 and midwall fractional shortening was found to be independent of LV hypertrophy, no adjustment was allowed for LV mass and relative wall thickness as continuous variables in the whole sample of 278 patients. The authors only report a significant independent inverse relation among the 178 patients with LV hypertrophy. A more appropriate approach would be testing whether the association stands in the whole population, and subsequently whether LV hypertrophy is a significant effect modifier of the relation. Second, the limited sample size and the tiny number of normotensive controls (only 25 patients) make it difficult to draw definite conclusions on the independent contribution of cardiotrophin-1 in stratifying the risk of LV systolic dysfunction. Third, most of the published studies on the association between circulating cardiotrophin-1 and LV structure and function have been obtained by the same research group [19–22,24–27,30], whereas studies from other groups could not confirm the same findings [29]. Also, the inclusion of hypertensive patients under blood pressure-lowering drug treatment may be misleading in the interpretation of the study results.

Does the available evidence support the use of cardiotrophin-1 as a screening tool for hypertensive heart disease in the clinical practice? A few years ago, Morrow and De Lemos [31] had proposed a set of three criteria to be fulfilled in order to define a new biological marker as clinically useful. First, accurate, reproducible, accessible assays with rapid turn-around and at a reasonable cost must be available to the clinician. Second, the biomarker must provide information that adds to or improves upon the current clinical assessment and is validated in more than one study. Third, knowing the result of the test should help in clinical decision-making. In our opinion, despite a growing body of evidence, cardiotrophin-1 may not yet fulfil the above criteria. Overall, the time is not yet ripe for recommending the widespread use of circulating cardiotrophin-1 as a clinically valuable tool for the biochemical detection and follow-up of hypertensive heart disease. However, the study by Ravassa et al.[30] represents a step toward a more comprehensive understanding of the factors underlying the role of cardiotrophin-1 in hypertensive heart disease, and their findings are provocative enough to be explored further in intervention trials aimed at assessing whether clinical monitoring guided by cardiotrophin-1 may improve the management of patients with hypertension-related cardiac disease. Moreover, the relationships between cardiotrophin-1 and systolic/diastolic (dys)function in hypertensive heart disease should be further evaluated in larger samples of patients, to properly evaluate the link between this biomarker and the extent of chronic pressure overload cardiac damage.

Back to Top | Article Outline


Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline


1. Krum H, Abraham WT. Heart failure. Lancet 2009; 373:941–955.
2. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557–1562.
3. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 2009; 119:3070–3077.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2005; 112:e154–e235.
5. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156:1789–1796.
6. de Simone G, Di Lorenzo L, Costantino G, Moccia D, Buonissimo S, de Divitiis O. Supernormal contractility in primary hypertension without left ventricular hypertrophy. Hypertension 1988; 11:457–463.
7. Lutas EM, Devereux RB, Reis G, Alderman MH, Pickering TG, Borer JS, Laragh JH. Increased cardiac performance in mild essential hypertension: left ventricular mechanics. Hypertension 1985; 7:979–988.
8. Aurigemma GP, Silver KH, Priest MA, Gaasch WH. Geometric changes allow normal ejection fraction despite depressed myocardial shortening in hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1995; 26:195–202.
9. de Simone G, Devereux RB, Celentano A, Roman MJ. Left ventricular chamber and wall mechanics in the presence of concentric geometry. J Hypertens 1999; 17:1001–1006.
10. Schillaci G, Verdecchia P, Reboldi G, Pede S, Porcellati C. Subclinical left ventricular dysfunction in systemic hypertension and the role of 24-h blood pressure. Am J Cardiol 2000; 86:509–513.
11. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension 2005; 45:412–418.
12. Schillaci G, Vaudo G, Pasqualini L, Reboldi G, Porcellati C, Verdecchia P. Left ventricular mass and systolic dysfunction in essential hypertension. J Hum Hypertens 2002; 16:117–122.
13. Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C, et al. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study. Am Heart J 2001; 141:784–791.
14. de Simone G, Devereux RB, Koren MJ, Mensah GA, Casale PN, Laragh JH. Midwall left ventricular mechanics: an independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93:259–265.
15. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678–683.
16. Celentano A, Palmieri V, Arezzi E, Mureddu GF, Sabatella M, Di Minno G, De Simone G. Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. J Hypertens 2003; 21:1415–1423.
17. de Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension 2001; 38:13–18.
18. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:2148–2159.
19. González A, López B, Martín-Raymondi D, Lozano E, Varo N, Barba J, et al. Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens 2005; 23:2297–2304.
20. López-Andrés N, Fortuno MA, Díez J, Zannad F, Lacolley P, Rossignol P. Vascular effects of cardiotrophin-1: a role in hypertension? J Hypertens 2010; 28:1261–1272.
21. López-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012; 60:563–573.
22. López B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, et al. Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens 2005; 23:625–632.
23. Talwar S, Downie PF, Squire IB, Davies JE, Barnett DB, Ng LL. Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001; 3:15–19.
24. López-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013; 61:120–129.
25. López B, Castellano JM, González A, Barba J, Díez J. Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension 2007; 50:977–983.
26. López B, González A, Querejeta R, Barba J, Díez J. Association of plasma cardiotrophin-1 with stage C heart failure in hypertensive patients: potential diagnostic implications. J Hypertens 2009; 27:418–424.
27. Monserrat L, López B, González A, Hermida M, Fernández X, Ortiz M, et al. Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J 2011; 32:177–183.
28. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 38:1485–1490.
29. Zile MR, DeSantis SM, Baicu CF, Stroud RI, Thompson SB, McClure SD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4:246–256.
30. Ravassa S, Beloqui O, Varo N, Barba J, López B, Beaumont J, et al. Association of cardiotrophin-1 with left ventricular systolic properties in hypertensive patients. J Hypertens 2013; 31:587–594.
31. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115:949–952.
© 2013 Lippincott Williams & Wilkins, Inc.